Advertisement

Topics

Alvogen Recalls Clindamycin Injection Over Lack of Sterility Assurance

10:18 EDT 19 Jun 2017 | PharmPro

Alvogen is voluntarily recalling seven lots of Clindamycin Injection USP ADD-Vantage Vials to the hospital/retail level due to microbial growth detected during a routine simulation of the manufacturing process.
Contributed Author: 
FDA MedWatch
Topics: 

Original Article: Alvogen Recalls Clindamycin Injection Over Lack of Sterility Assurance

NEXT ARTICLE

More From BioPortfolio on "Alvogen Recalls Clindamycin Injection Over Lack of Sterility Assurance"

Advertisement
Quick Search
Advertisement
Advertisement